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Liver fibrosis is the progressive accumulation of connective tissue in the liver, which 
can be caused by chronic liver injury of various etiologies. The most common causes of 
liver fibrosis are infection with hepatitis B or C virus, alcohol abuse, drugs, 
schistosomiasis infection, and autoimmune diseases. The development of fibrosis in the 
liver is the result of a multicellular process, which is described in more detail in chapter 
1. Briefly, injured liver cells produce several mediators that initiate the activation and 
proliferation of hepatic stellate cells and/or other fibrogenic cells and the production of 
excess extracellular matrix. In addition, liver injury leads to the recruitment of immune 
cells into the liver and to the activation of local Kupffer cells, which further promotes 
the fibrotic process. The increased deposition of extracellular matrix is mainly caused 
by the increased production of matrix proteins by activated stellate cells. In addition, 
matrix breakdown is decreased due to alterations in the expression levels of 
metalloproteinases and their inhibitors. These processes result in accumulation of 
extracellular matrix and in profound changes in its protein composition, which in turn 
can further contribute to the progression of fibrosis. The extent of fibrosis and 
inflammation depends on the type and duration of the liver injury. When injury is 
acute, the fibrotic response is taken over by regeneration, with replacement of 
apoptotic or necrotic cells, removal of scar tissue, and resolution of inflammation. 
However, when injury is sustained, the regeneration process is insufficient and 
functional liver tissue is gradually replaced by extracellular matrix. As this process 
progresses, morbidity and mortality due to disease-related complications will increase 
unless the causal factor is removed.  
As no effective treatment for liver fibrosis is available yet, extensive research is ongoing 
to further study the underlying mechanisms of the disease and to develop new anti-
fibrotic drugs. To date, studies on the development of anti-fibrotic drugs rely mostly on 
in vivo animal experiments. These models can incorporate the effects of the 
extracellular milieu during hepatic stellate cell activation and fibrogenesis accurately, 
but are largely restricted to rodents and therefore may be of limited predictive value for 
human disease. In addition, in vivo models give high discomfort to the experimental 
animals and should therefore be avoided when possible. By using in vitro models, the 
use of experimental animals can be greatly reduced because various experimental 
conditions can be tested using cells or tissue from only one animal, which is in most 
cases not possible in in vivo experiments. Importantly, by using human cells or tissue, 
species differences can be addressed, and the results obtained with rodent cells or tissue 
could be validated for their relevance to the human situation. However, as described in 
chapter 1, the choice of in vitro models for liver fibrosis is still limited. Current in vitro 
models, which rely on cell cultures of primary or immortalized cells, have contributed 
significantly to the understanding of liver fibrosis but lack a physiologic milieu that can 
accurately incorporate the effects of cell-cell and cell-extracellular matrix interactions, 
which play an important role in the development of liver fibrosis. Hence there persists 
a need for an in vitro system that can mimic the in vivo situation more closely.  
 
  






AIM OF THE THESIS 
Recently, precision-cut liver slices came into the attention as a potential in vitro model 
for the study of stellate cell activation and liver fibrosis. As discussed in chapter 6, in 
contrast to current in vitro models, liver slices provide a multicellular system in which 
cell-cell and cell-extracellular matrix interactions are maintained and may at least 
partially account for the influence of the immune system and central nervous system in 
the development of liver fibrosis. Liver slices are extensively used to study drug 
metabolism and toxicity, however, studies describing the use of liver slices for the study 
of hepatic stellate cell activation and fibrogenesis are still limited. Therefore, the aim of 
the research described in this thesis was to evaluate liver slices as a tool for the study of 
fibrosis and as a test system for anti-fibrotic drugs.  
 
RESULTS 
The studies described in this thesis resulted in the development of three promising in 
vitro models for liver fibrosis. First, as described in chapter 2 and 3, we have developed 
a technique to induce early hepatic stellate cell activation in rat and human liver slices. 
This was achieved by incubation of the liver slices with the fibrogenic compound 
carbon tetrachloride, which in vivo induces fibrosis via its conversion into free radicals 
by hepatocytes and the subsequent formation of lipid peroxides and other mediators 
that activate hepatic stellate cells, both directly and indirectly via Kupffer cells. We 
showed that incubation of rat and human liver slices with carbon tetrachloride results 
in early stellate cell activation, as was determined by the expression levels of several 
markers for stellate cell activation and fibrogenesis. Given the mechanism of fibrosis 
development due to carbon tetrachloride in vivo, this stellate cell activation can likely 
only occur because all liver cell types are present in the liver slice and cell-cell 
interactions are maintained. This in vitro model could thus provide a system to study 
multicellular mechanisms leading to early hepatic stellate cell activation in human and 
rat liver tissue.  
To further evaluated this model as a tool to test the effects of anti-fibrotic compounds, 
human liver slices were incubated simultaneously with carbon tetrachloride and the 
anti-fibrotic compound pentoxifylline (chapter 4). The anti-fibrotic effects of 
pentoxifylline are generally attributed to inhibition of platelet-derived growth factor 
(PDGF) signaling. In human liver slices incubated with carbon tetrachloride, 
pentoxifylline could not inhibit early stellate cell activation, although it did have 
inhibitory effects on fully activated stellate cells or other (myo)fibroblast populations in 
the liver slices. Previously, it was reported that responsiveness of stellate cells to PDGF 
might require that the cells are fully activated. If the inhibitory effect of pentoxifylline 
is solely mediated via its effect on PDGF signaling, this could explain why 
pentoxifylline is unable to inhibit the carbon tetrachloride-induced early stages of 
hepatic stellate cell activation. We concluded that, although this model could be used to 
study the effects of anti-fibrotic drugs on early hepatic stellate cell activation in human 
liver, other types of inhibitors, which act on different pathways involved in the 






   
 
 
Secondly, in the studies described in chapter 4 and 5 we determined the mRNA 
expression of markers for stellate cell activation and fibrogenesis during incubation of 
rat and human liver slices. We observed a decrease in mRNA expression of these 
markers during the first hours of incubation, followed by increasing gene expression 
after prolonged incubation, which suggests that a fibrotic process occurs in the liver 
slices. Similar to the in vivo situation, both activated stellate cells and other 
(myo)fibroblast populations appeared to be involved in this process. Stellate cell 
activation and fibrogenesis occurring in liver slices generated from normal liver tissue, 
suggests that the induction of these processes is intrinsically related to the preparation 
or culturing method used. Factors in the method used that might trigger the fibrotic 
process are ischemia-reperfusion injury, the presence of high oxygen tension during 
incubation, cell death during incubation, or accumulation of (waste) products in the 
slices. Pilot experiments indicated that the damage to the cells on the surface caused by 
the cutting of the slices does not play a major role in triggering the spontaneous fibrotic 
process in liver slices and that accumulation of bile salts, which is potentially 
fibrogenic, does not occur during incubation of the liver slices. Incubation of rat and 
human liver slices in the presence of the anti-fibrotic compound pentoxifylline resulted 
in significant inhibition of the spontaneous fibrotic process. From these results it was 
concluded that this model provides a simple system to study fibrogenesis in the liver 
and to test anti-fibrotic drugs in a multicellular environment, closely resembling the in 
vivo situation. Further evaluation of the processes underlying both the initial decreased 
expression of stellate cell activation and fibrogenesis markers and their subsequent 
increased expression after prolonged incubation is necessary to fully characterize this 
model. 
Thirdly, in the studies described in chapter 5 we evaluated liver slices generated from 
fibrotic rat liver tissue as a tool to study fibrosis and test anti-fibrotic compounds. 
Fibrotic rat liver slices were generated from rat liver three weeks after bile-duct 
ligation. These livers showed clear signs of fibrosis that were retained after the slicing 
procedure, indicating that the liver slices still were fibrotic. During incubation up to 48 
hours, viability of the fibrotic liver slices and the different liver cell types therein was 
maintained, with retained cell-cell interactions. Incubation of fibrotic rat liver slices 
resulted in similar changes in the expression of markers for stellate cell activation and 
fibrogenesis as described above for normal rat liver slices, with a more pronounced 
increase of these markers after prolonged incubation. The inhibition of the latter 
process by the anti-fibrotic drugs pentoxifylline, gleevec, and dexamethasone indicated 
that fibrotic rat liver slices could be a useful tool to test anti-fibrotic compounds. A 
comparison of the results obtained with fibrotic liver slices and other models for liver 
fibrosis with respect to the anti-fibrotic effects of the different compounds studied 
showed that, despite the multicellular, fibrotic milieu in these liver slices, extrapolation 
to the in vivo situation might remain difficult and may depend on the type of fibrosis. 
Nevertheless, fibrotic liver slices could provide the unique opportunity to study 
progressed stages of fibrosis and to test the effects of anti-fibrotic compounds in a 
multicellular and, importantly, fibrotic environment, which is not possible using other 
in vitro models or normal rat liver slices. 
 
  







As discussed in more detail in chapter 6, liver slices provide a multicellular in vitro 
model for the liver in which cell-cell and cell-extracellular matrix interactions are 
maintained. These interactions play an important role in the development of liver 
fibrosis in vivo, but are not adequately incorporated in current available in vitro models 
for liver fibrosis. The results of our studies indicate that liver slices could provide a 
promising alternative for the study of liver fibrosis in vitro. The development of the 
combination of models described in this thesis may contribute substantially to the 
reduction, refinement, and possible replacement of animal experiments. In addition, the 
use of human liver tissue in these in vitro models may improve the predictive value for 
man.  
 
 
 
 
